Go Back

ESKE GLOBAL FASHIONS PRIVATE LIMITED

Eske Paris

U18109MH2022PTC375567

Get Comprehensive Report

₹1,999.00 ₹3,998.00
Suggest Edit Last updated: Jul 2, 2025
Key Metrics
  • No. of Employees43
  • Founded Year 2012
  • Company StagePrivate Limited Company
  • Total Funding₹20 Cr
  • Industry

  • Headquarter
  • Company StatusActive
About Eske Paris

eské offers the best in accessible luxury and lifestyle. A legacy of exquisite craftsmanship, market leadership and manufacturing over three decades has allowed us to gain domain expertise and unparalleled quality standards. Only the finest leathers and globally-sourced hardware are used to create the perfect collections for you. Made for the modern consumer's discerning lifestyle, with a seamless blend of functionality and aesthetic.

Business Model

Eske Pris is a brand offering handbags for women. The company offers a range of products including handbags, totes, shoulder bags, laptop bags, wallets. Apart from this it also offers belts and footwear.

Top Competitors
AD
AdornaU74999UP2018PTC100815
FL
Fs LifeU18101DL2016PTC291050
SA
SarjaaU74999TN2021PTC141197
FA
FabyouareU74999DL2017PTC317246
Eske Paris Funding Details
Funding Highlights
Latest Funding Roundpre-Series A
Total Funding Raised₹20 Cr
No. of Investments Made0
Total No. of Acquisitions0
Lead Investors1
Investors
  • Mistry Ventures
Funding Details
TheKredible's detailed funding report contains info about Funding raised by the company along with Lead Investors, Investors, Shareholding Strcuture, and its Investments & Acquisitions.
₹799.00 ₹1,598.00
Funding History
TheKredible's 'Funding History' report provides deep insights of Funding with list of Lead Investors
₹399.00 ₹798.00
Funding Per Year
A Funding report of the company's overall funding on yearly basis, segregated by the team TheKredible.
₹199.00 ₹398.00
Eske Paris Financial Details
Financial Highlights
FY 2023-24 Revenue₹10.28 Cr
FY 2023-24 Expenses₹15.87 Cr
FY 2023-24 Profit/Loss-₹5.58 Cr
Net Cash Flow From Operations-₹4.59 Cr
Full Financial Details
Detailed report containing info about Business Model, year-wise Financial Comparison, Ratio Analysis and detailed Revenue and Expense breakdowns.
₹799.00 ₹1,598.00
Financial Comparison
A detailed report of year-wise Financial Comparison of the company
₹430.00 ₹860.00
Revenue Breakdown
A report and breakdown of the company's year-wise revenue streams.
₹399.00 ₹798.00
Expense Breakdown
A report and breakdown of the company's year-wise expenditures.
₹399.00 ₹798.00
Shareholding Structure
Team at TheKredible has gone through several ROC filings and portrayed Shareholding Structure of the company.
₹499.00 ₹998.00
Financial Ratio
Analysis of Financial Ratios which gives quick insights about the company's profitability and capital efficiency.
₹199.00 ₹398.00
Eske Paris Key People
People Metrics
Current Core Team1
Board Members/Directors3

Core Team

SK
Shivam KhannaFounder & CEO

Board Members/Directors

SJ
Sanjay Jawaharlal KhannaDirector
SK
Sailesh Khanna JawaharlalDirector
SS
Shivam Sanjay KhannaDirector
Eske Paris Documents

AY - 2022-23

Profit and Loss statement - Eske Paris - 2022-23.pdf
TheKredible's experts has summarized the Profit and Loss Statement of Eske Paris for FY 2022-23.
₹249.00 ₹498.00
Balance Sheet - Eske Paris - 2022-23.pdf
TheKredible's experts has summarized the Balance Sheet of Eske Paris for FY 2022-23.
₹249.00 ₹498.00

AY - 2023-24

Profit and loss statement - Eske Paris - 2023-24.pdf
TheKredible's experts has summarized the Profit and Loss Statement of Eske Paris for FY 2023-24
₹249.00 ₹498.00
Balance sheet - Eske Paris - 2023-24.pdf
TheKredible's experts has summarized the Balance Sheet of Eske Paris for FY 2023-24
₹249.00 ₹498.00

Subscribe to our newsletter to stay updated

Weekly Funding Reports
Funding Report
Weekly Funding Report [30 Jun- 05 Jul, 2025]
Monthly Funding Reports
Funding Report
Indian startups raised a total of $1.14 billion ac...

Get your Customised Report

With an exclusive 20% off on your order

Latest Industry Reports
Industry Report
HealthTech’s Rebound: After a Downturn, HealthTech...